Community-acquired pneumonia (CAP) remains a major cause of childhood illness and mortality worldwide, particularly in low- and middle-income countries, where persistent inflammation and lung injury may hinder recovery despite antibiotic treatment. To address this challenge, a study evaluated the efficacy of oral pentoxifylline (PTX) administered alongside standard antibiotic and supportive therapies in improving clinical outcomes among hospitalized children with CAP in 106 children with a median age of 5 years. The study found that, after 10 days of treatment, children receiving pentoxifylline (PTX) showed significantly lower respiratory rates compared with controls (29.17 ± 4.38 vs.
34.02 ± 8.29 breaths/min) along with higher oxygen saturation levels (97.28 ± 1.32% vs. 96.26 ± 1.55%). The PTX group also demonstrated significant laboratory improvements, including higher hemoglobin and…
